U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention
You may also be interested in...
USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis
The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis
One Year After Spike In American Deaths From China-sourced Contaminated Heparin, U.S. Pharmocopeia Issues Revised Standards
BEIJING - When heparin sourced from China mysteriously and suddenly began triggering a spike in extreme adverse reactions and deaths across American hospitals 18 months ago, U.S. FDA rapidly called on the U.S. Pharmacopeial Convention to help devise new testing methods to determine the purity and quality of the blood thinner
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
BEIJING - In moves that could ultimately help elevate safety and quality standards for drugs produced across Asia, including those exported to North America, the United States Pharmacopeial Convention has signed a series of agreements with China and the Association of Southeast Asian Nations on closer scientific exchanges and joint testing of pharmaceuticals